News
CHMA
--
0.00%
--
3 “Strong Buy” Healthcare Stocks Under $5 With Triple-Digit Growth Prospects
For those that thought the extreme market volatility was behind us, think again. This month, another burst of volatility was brought on by concerns about the U.S. economic recovery, hefty valuations, and a second wave of COVID-19. While challenging at times, Wall Street pros believe the healthcare space
TipRanks · 3d ago
Chiasma to Participate in Two September Investor Conferences
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that management
GlobeNewswire · 09/08 13:00
Crinetics Pharmaceuticals- Superior Molecules In Endocrinology
Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.
Seeking Alpha - Article · 09/01 17:35
Chiasma announces U.S. commercial launch and availability of MYCAPSSA
Chiasma ([[CHMA]] -0.7%) has launched MYCAPSSA capsules in the United States for patients with acromegaly.MYCAPSSA, the first and only oral somatostatin analog approved by the U.S. Food and Drug Administration
Seekingalpha · 08/31 13:39
Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly
GlobeNewswire · 08/31 13:00
Chiasma Announces US Commercial Launch And Availability Of MYCAPSSA Oral Somatostatin Analog For Patients With Acromegaly
Chiasma advances U.S. commercial launch originally planned for fourth quarter NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a commercial stage biopharmaceutical company utilizing its
Benzinga · 08/31 12:03
Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Simply Wall St. · 08/17 19:01
Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism
Benzinga · 08/17 12:06
Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the online publication
GlobeNewswire · 08/17 12:00
Chiasma Q2 EPS $(0.50) Misses $(0.38) Estimate
Chiasma (NASDAQ:CHMA) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.38) by 31.58 percent. This is a 100 percent decrease over losses of $(0.25) per share from the same
Benzinga · 08/10 20:42
Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness
MYCAPSSA® U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarterCompany to host conference call today, August 10, at 5pm ETNEEDHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Chiasma,
GlobeNewswire · 08/10 20:05
Chiasma to Report Second Quarter 2020 Results on August 10
Company to host conference call and webcast at 5:00 p.m. ETNEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast
GlobeNewswire · 08/03 20:01
Chiasma's octreotide shows sustained benefit in acromegaly extension study
Seeking Alpha · 07/27 20:31
UPDATE: Chiasma Says Mean Of IGF-1 Levels For Population Of All MYCAPSSA-Treated Patients That Completed 36-Week Core CHIASMA OPTIMAL Trial And Continued Into OLE 'was maintained within normal limits at the end of the 48-week OLE period'
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within
The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within · 07/27 20:04
UPDATE: Chiasma Says 'All MYCAPSSA responders (IGF-1 within normal limits) who enrolled into the OLE completed the 48-week period; 93% maintained their response at the end of this period;
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within
The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within · 07/27 20:03
Chiasma Announces 48-Week Safety And Efficacy Data From Open-Label Extension Study Of CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within
The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within · 07/27 20:03
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly
\-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within normal limits at the end of the 48-week OL
GlobeNewswire · 07/27 20:01
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
Were Hedge Funds Right About Chiasma Inc (CHMA)?
Insider Monkey · 07/09 02:21
Chiasma prices public offering at $4/share
Seeking Alpha - Article · 07/01 13:42
Webull provides a variety of real-time CHMA stock news. You can receive the latest news about Chiasma through multiple platforms. This information may help you make smarter investment decisions.
About CHMA
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
More